Debt to Equity Ratio Chart

View Debt to Equity Ratio for BRTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 2011. Start Trial.
Date Value
March 31, 2026 0.0114
December 31, 2025 0.4012
September 30, 2025 0.00
June 30, 2025 0.00
March 31, 2025 0.00
December 31, 2024 0.00
September 30, 2024 0.0042
June 30, 2024 0.0077
March 31, 2024 0.0085
December 31, 2023 0.0162
September 30, 2023 0.0155
June 30, 2023 0.0189
March 31, 2023 0.0199
December 31, 2022 0.019
September 30, 2022 0.0196
June 30, 2022 0.0195
March 31, 2022 0.0195
December 31, 2021 0.0311
September 30, 2021 -1.299
June 30, 2021 -1.446
March 31, 2021 -1.939
December 31, 2020 -3.599
September 30, 2020 -0.1099
June 30, 2020 -0.0886
March 31, 2020 -0.4909
Date Value
December 31, 2019 -0.6069
September 30, 2019 -0.6182
June 30, 2019 -0.6374
March 31, 2019 -0.5228
December 31, 2018 -0.4802
September 30, 2018 -0.4858
June 30, 2018 -0.4898
March 31, 2018 -0.4913
December 31, 2017 -0.5358
September 30, 2017 -0.4389
June 30, 2017 -0.447
March 31, 2017 -0.4404
December 31, 2016 -0.4317
September 30, 2016 -0.3997
June 30, 2016 -0.455
March 31, 2016 -0.3727
December 31, 2015 -0.3364
September 30, 2015 -0.4421
June 30, 2015 -0.3988
March 31, 2015 -0.7809
December 31, 2014 -0.8337
September 30, 2014 -0.8978
June 30, 2014 -0.8375
March 31, 2014 -0.7833
December 31, 2013 -0.8257

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Myriad Genetics, Inc. 0.6927
CareDx, Inc. 0.0452
Natera, Inc. 0.1309
Exagen, Inc. 2.264
Sera Prognostics, Inc. 0.0505